Clinical Trials

Clinical trials are research studies that test new potential treatments for a disease. Talk to your doctor about possible clinical trials that could be helpful to you.

hepbfoundation hepdelta banner 3

Glossary: HBV = Hepatitis B, CHB = Chronic hepatitis B, HDV = Hepatitis D, CHD = Chronic hepatitis D, ALT = Alanine aminotransferase, AST = Aspartate aminotransferase, EOT = End of Treatment, NTCP = Sodium/taurocholate cotransporting polypeptide, LNF-containing regimens = Lonafarnib-containing regimens


Recruiting - Phase 3 Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon-Alfa-2a (D-LIVR) - U.S. and International

Two LNF-containing regimens will be evaluated in the D-LIVR Phase 3 study: (1) LNF/RTV/PEG IFN-alfa-2a and (2) LNF/RTV. Each of these arms will have efficacy endpoints that measure clinical benefit with regard to viral suppression and ALT normalization. For each LNF-containing regimen, a composite endpoint of EOT (48 weeks) virologic response and ALT normalization will be used. Virologic response will be defined as a 2 log10 IU/mL reduction from baseline. Contact: John Ferraro 650-272-6138 or DLIVR@eigerbio.com and refer to identifier NCT03719313. Also visit www.d-livrstudy.com for more information. 

Currently recruiting patients in:

United States

  • California, Florida, Iowa, Michigan, New York, Oklahoma, Texas

Internationally

  • Belguim, Bulgaria, Canada, France, Greece, Israel, Italy, Republic of Moldova, Pakistan, New Zealand, Romania, Spain, Sweden, Taiwan, Turkey, UK 

Recruiting - Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide (Myrcludex B) in Patients With Chronic Hepatitis Delta - International

This study is designed to assess the long-term efficacy and safety of Bulevirtide in patients with HDV. Contact Dr. Yana Deloveri at +74957265253 or email deloveri@myr-pharma.com and refer to identifier NCT03852719.

Currently recruiting patients in:

United States

  • New York

Internationally

  • Germany, Italy, Russia, Sweden

Recruiting - Phase 2b Study of Bulevirtide (With Peginterferon Alfa-2a) in Patients With Chronic Hepatitis Delta - International

A Multicenter, Open-label, Randomized Phase 2b Clinical Study. Contact: Yana Deloveri at +491777168259 or email deloveri@myr-pharma.com and refer to identifier NCT03852433.

Currently recruiting patients in:

  • France
  • Republic of Moldova
  • Romania
  • Russia

Recruiting - The Hepatitis Delta International Network - International

Multicenter, observational study (patients will not receive any treatment) that will build a registry of HDV patients around the world and collect clinical information. Contact: Dr. Heiner Wedemeyer at Wedemeyer.Heiner@mh-hannover.de or Dr. Svenja Hardtke at Hardtke.Svenja@mh-hannover.de and refer to identifier NCT02375906.

Currently recruiting patients in: 

  • Belgium
  • Brazil
  • Georgia
  • Germany
  • Greece
  • Italy
  • Republic of Moldova
  • Pakistan
  • Romania
  • Spain
  • Vietnam

May Still Be Recruiting - Phase 2 Study of Ezetimibe for Patients With Chronic Hepatitis Delta – International

Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry that include two hydrophobes and one hydrogen bond acceptor. Therapy with ezetimibe may lead to decline in HDV levels. The aim of the study is to evaluate the utility of ezetimibe in patients with CHD. Contact: Zaigham Abbas at 922135862937 or email drzabbas@gmail.com and refer to identifier NCT03099278.

Currently recruiting patients in:

  • Sindh, Pakistan

Recruiting - Evaluation of Patients with Liver Disease, Including Hepatitis Delta – U.S.

Evaluate, investigate and follow-up patients suffering from acute and chronic liver disease. Qualified patients may be able to participate in other offered studies. Contact Nancy Fryzek at 301-435-6122 nancy.fryzek@nih.gov or Dr. T. Jake Liang at 301-496-1721 jakel@mail.nih.gov and refer to identifier NCT00001971.

Currently recruiting patients in:

  • Bethesda, Maryland (National Institute of Health)

Recruiting - Hepatitis B Research Network Adult Cohort Study (HBRN) - U.S. and Canada

The primary purpose of this study is to describe participants with hepatitis B virus (HBV) infection and identify factors that may cause the disease to activate or worsen. This study includes people who also have hepatitis delta or have tested positive for the hepatitis delta antibody. This is an observational study where no treatment will be administered. Contact Frani M Averbach at 412-624-3773, or email HBRNDCC@edu.pitt.edu and refer to identifier NCT01263587.

Currently recruiting patients in:

  • United States: California, Hawaii, Maryland, Massachusetts, Michigan, Minnesota, North Carolina, Texas, Virginia, Washington
  • Canada: Ontario

Clinical Trial Process

Clinical Trial Process FlowChart

Learn more about all current hepatitis delta clinical trials.


Additional Resources

www.clinicaltrials.gov is a service of the National Institutes of Health that provides a list of all the clinical trials that are being carried out in the United States. You can search for a clinical trial by disease, drug therapy, or trial location.

www.searchclinicaltrials.org offers a free search service by the Center for Information and Study on Clinical Research Participation (CISCRP) to help you find a clinical trial that may be right for you.

Hepatitis B Clinical Trials Page is a list that is updated each month by the Hepatitis B Foundation of clinical trials specific for hepatitis B.

Updated January 2020.